In addition, SLFN11, as a general target, is considered to exert a vital regulatory function in improving the sensitivity of multiple malignancies to chemotherapy, such as ovarian cancer, prostate cancer, small cell lung cancer, and so on (38–40). This evidence concerns the gene SLFN11 and ovarian cancer.